<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03989115</url>
  </required_header>
  <id_info>
    <org_study_id>RMC-4630-02</org_study_id>
    <nct_id>NCT03989115</nct_id>
  </id_info>
  <brief_title>Dose-Escalation and Dose-Expansion of RMC-4630 and Cobimetinib in Relapsed/Refractory Solid Tumors</brief_title>
  <official_title>A Phase 1b/2, Open-Label, Multicenter Dose-Escalation and Dose-Expansion Study of the Combination of RMC-4630 and Cobimetinib in Adult Participants With Relapsed/Refractory Solid Tumors With Specific Genomic Aberrations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Revolution Medicines, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Revolution Medicines, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and
      pharmacodynamic (PD) proﬁles of RMC-4630 and cobimetinib in adult participants with
      relapsed/refractory solid tumors with specific genomic aberrations and to identify the
      recommended Phase 2 dose (RP2D).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This open-label, phase 1b/2 dose-escalation and dose-expansion study is designed to evaluate
      the safety and maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of RMC-4630
      in combination with cobimetinib in participants with relapsed/refractory solid tumors.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 3, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events (AEs)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Incidence, nature, and severity of treatment-emergent AEs and SAEs, graded according to the NCI CTCAE v5 for the combination of RMC-4360 and cobimetinib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with dose limiting toxicities (DLTs)</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence and nature of DLTs for the combination of RMC-4630 and cobimetinib</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Peak plasma concentration of RMC-4630 and cobimetinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Time to achieve peak plasma concentration of RMC-4630 and cobimetinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Area under the plasma concentration time curve of RMC-4630 and cobimetinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Elimination half-life of RMC-4630 and cobimetinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio</measure>
    <time_frame>up yo 3 years</time_frame>
    <description>Ratio of accumulation of RMC-4630 and cobimetinib from a single dose to steady state with repeated dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Overall response rate of RMC-4630 and cobimetinib per RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Duration of response of RMC-4630 and cobimetinib per RECIST v1.1</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>RMC-4630 and Cobimetinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RMC-4630 and Cobimetinib for oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RMC-4630</intervention_name>
    <description>RMC-4630 for oral administration</description>
    <arm_group_label>RMC-4630 and Cobimetinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cobimetinib</intervention_name>
    <description>Cobimetinib for oral administration</description>
    <arm_group_label>RMC-4630 and Cobimetinib</arm_group_label>
    <other_name>GDC-0973, XL518</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years

          -  Participants who have advanced solid tumors that have failed, are intolerant to, or
             are considered ineligible for standard of care anti-cancer treatments including
             approved drugs for oncogenic drivers in their tumor type.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤1

          -  Participants must have one of the following genotypic aberrations: KRAS mutations and
             amplifications, BRAF Class 3 mutations, or NF1 LOF mutations

          -  Adequate hematological, hepatic, and renal function

          -  Capable of giving signed informed consent form (ICF). Willing and able to compile with
             study requirements and restrictions

          -  Life expectancy &gt;12 weeks

          -  Female of childbearing potential and males with partners of childbearing potential
             must comply with effective contraception criteria .

        Exclusion Criteria:

          -  Primary central nervous system (CNS) tumors.

          -  Known or suspected leptomeningeal or brain metastases or spinal cord compression.

          -  Clinically significant cardiac disease

          -  Active, clinically signiﬁcant interstitial lung disease or pneumonitis

          -  History or current evidence of retinal pigment epithelial detachment (RPED), central
             serous retinopathy, retinal vein occlusion (RVO), or predisposing factors to RPED or
             RVO

          -  Known HIV infection or active/chronic hepatitis B or C infection.

          -  Any other unstable or clinically signiﬁcant concurrent medical condition that would,
             in the opinion of the investigator, jeopardize the safety of a participant, impact
             their expected survival through the end of the study participation, and/or impact
             their ability to comply with the protocol prior/concomitant therapy

          -  Females who are pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Revolution Medicines, Inc.</last_name>
    <role>Study Director</role>
    <affiliation>Revolution Medicines, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Revolution Medicines, Inc.</last_name>
    <phone>(650) 779-2300</phone>
    <email>CT-Inquiries@RevMed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Honor Health Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joyce Schaffer</last_name>
      <phone>480-323-1791</phone>
      <email>clinicaltrials@honorhealth.com</email>
    </contact>
    <investigator>
      <last_name>Michael Gordon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianna Koczywas, MD</last_name>
      <phone>626-256-4673</phone>
      <email>mkoczywas@coh.org</email>
    </contact>
    <investigator>
      <last_name>Marianna Koczywas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC Irvine - Chao Family Comprehensive Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sai-Hong Ignatius Ou, MD</last_name>
      <phone>714-456-8014</phone>
      <email>ignatius.ou@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Sai-Hong Ignatius Ou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinne Turrell</last_name>
      <email>ceturrell@ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan Riess, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC San Francisco - Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Lopez</last_name>
      <phone>415-885-3728</phone>
      <email>Melissa.Lopez@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Caroline McCoach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Califano</last_name>
      <phone>720-848-0592</phone>
      <email>Kristen.Califano@cuanschutz.edu</email>
    </contact>
    <investigator>
      <last_name>Jose Pacheco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute, Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shawn Reese</last_name>
      <phone>404-778-8040</phone>
      <email>shawn.reese@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Conor Steuer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenn Hale</last_name>
      <email>jennhale@jhu.edu</email>
    </contact>
    <investigator>
      <last_name>Julie Brahmer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Graham</last_name>
      <email>Christopher_graham@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Kimmie Ng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Misako Nagasaka</last_name>
      <phone>313-576-8753</phone>
      <email>nagasakm@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Misako Nagasaka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute - Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Neagle</last_name>
      <phone>980-442-2303</phone>
      <email>Heather.Neagle@atriumhealth.org</email>
    </contact>
    <investigator>
      <last_name>Mohamed Salem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carly Pilcher</last_name>
      <email>Carly.Pilcher@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Gregory Otterson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma - Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dena Suthers</last_name>
      <phone>405-271-8778</phone>
      <email>dena-suthers@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Susanna Ulahannan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Institute, Franz Clinic</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Lopez</last_name>
      <email>CanRsrchStudies@providence.org</email>
    </contact>
    <investigator>
      <last_name>Rachel Sanborn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Edelman, MD</last_name>
      <phone>215-728-5682</phone>
      <email>martin.edelman@fccc.edu</email>
    </contact>
    <investigator>
      <last_name>Martin Edelman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute - Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Taylor</last_name>
      <phone>615-524-4037</phone>
      <email>lauren.taylor2@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Johanna Bendell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dell Seton Medical Center at University of Texas</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Staci Eaton</last_name>
      <phone>512-495-5500</phone>
      <email>staci.eaton@austin.utexas.edu</email>
    </contact>
    <investigator>
      <last_name>Gail Eckhardt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists (Fairfax) - USOR</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Spira, MD</last_name>
      <email>alexander.spira@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Alexander Spira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cancer Connect</last_name>
      <phone>800-622-8922</phone>
    </contact>
    <investigator>
      <last_name>Dustin Deming, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 14, 2019</study_first_submitted>
  <study_first_submitted_qc>June 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2019</study_first_posted>
  <last_update_submitted>June 11, 2020</last_update_submitted>
  <last_update_submitted_qc>June 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SHP2</keyword>
  <keyword>PTPN11</keyword>
  <keyword>NSCLC</keyword>
  <keyword>KRAS G12</keyword>
  <keyword>BRAF Class 3</keyword>
  <keyword>NF1 LOF</keyword>
  <keyword>KRAS amplification</keyword>
  <keyword>KRAS mutations</keyword>
  <keyword>advanced solid tumor</keyword>
  <keyword>advanced solid malignancies</keyword>
  <keyword>melanoma</keyword>
  <keyword>skin cancer</keyword>
  <keyword>ovarian cancer</keyword>
  <keyword>pancreatic cancer</keyword>
  <keyword>endometrium/uterus cancer</keyword>
  <keyword>bladder cancer</keyword>
  <keyword>cervical cancer</keyword>
  <keyword>carcinoma, non-small-cell lung</keyword>
  <keyword>neoplasm, squamous cell</keyword>
  <keyword>carcinoma, squamous cell</keyword>
  <keyword>esophageal neoplasms carcinoma, bronchogenic</keyword>
  <keyword>bronchial neoplasms</keyword>
  <keyword>lung neoplasms</keyword>
  <keyword>respiratory tract neoplasms</keyword>
  <keyword>thoracic neoplasms</keyword>
  <keyword>neoplasms by site</keyword>
  <keyword>neoplasms</keyword>
  <keyword>lung diseases</keyword>
  <keyword>respiratory tract diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

